The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 40.00
Ask: 43.00
Change: 0.00 (0.00%)
Spread: 3.00 (7.50%)
Open: 41.50
High: 41.50
Low: 41.50
Prev. Close: 41.50
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Agreement with FCT, Universidade NOVA de Lisboa

14 Sep 2016 11:50

RNS Number : 8333J
Frontier IP Group plc
14 September 2016
 

AIM: FIPP

14 September 2016

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

Agreement with the Faculty of Science and Technology of Universidade NOVA de Lisboa

 

Frontier IP, which specialises in the commercialisation of intellectual property, is pleased to announce that it has today signed an agreement with the Faculty of Science and Technology within the Universidade NOVA de Lisboa, Portugal ("FCT NOVA") to assist with its spin-off and licensing activities emerging from its research programmes. This partnership is Frontier IP's second in Portugal and reflects the Group's view that there is significant opportunity in the region.

 

The Universidade NOVA de Lisboa is a research-intensive university (QS Top Universities 2016) and FCT NOVA, its engineering school, has particular research strengths in Materials, Environment, Energy, Biotechnology, Conservation and Restoration. Frontier IP and FCT NOVA will work together to maximise the commercial value of intellectual property developed within or owned by FCT NOVA. Frontier IP will receive a share of equity in each spin-off company created by FCT NOVA, as well as a share in the licensing revenue it receives.

 

FCT NOVA is an active research collaborator, both within Portugal and internationally, and its partners include Massachusetts Institute of Technology (MIT), the University of Carnegie Mellon and the University of Texas at Austin, amongst others. The collaboration with Frontier IP aims to accelerate value creation from the research generated within FCT NOVA and provide access to early stage funding, commercialisation expertise and a wider network of industrial partners.

 

The signing of the agreement was attended by Her Majesty's Ambassador to the Portuguese Republic, Mrs Kirsty Hayes. Addressing the audience, the Ambassador emphasised the importance of effective commercialisation of the intellectual property being generated through the investment in research and development in Portugal's universities. The UK has strong experience of intellectual property commercialisation and it has been a principle focus for British universities to develop a portfolio of intellectual property which has relevance to the business world.

 

Her Majesty's Ambassador to the Portuguese Republic, Mrs Kirsty Hayes, said:

 

"I am delighted by the announcement of this important agreement between Frontier IP and FCT NOVA, which will drive the commercialisation of intellectual property from one of the leading Portuguese universities, which has a strong reputation for investment in research and development. This agreement represents a further strengthening of collaboration between Portugal and the United Kingdom."

 

Neil Crabb, Chief Executive of Frontier IP, said:

 

"We are delighted that FCT NOVA has chosen us as its commercialisation partner. This agreement gives us access to FCT NOVA's excellent research base and builds on the strong relationships with the industrial partners and academic institutions which we have already established in the region. We are looking forward to working with FCT NOVA to further develop and commercialise its strong intellectual property portfolio."

 

Dr. Fernando Santana, Director of FCT NOVA, said:

 

"Frontier IP has a strong reputation in the commercialisation of university-based technologies. We hope that this agreement will bring increased international visibility to FCT NOVA's portfolio, making it an even more successful institution by maximizing the impact of its knowledge. This shows FCT NOVA's commitment to innovation, which benefits the institution and the wider society it serves."

 

Enquiries

 

Frontier IP Group Plc

 

T: 0131 240 1251

Neil Crabb, Chief Executive

 

 

Company website: www.frontierip.co.uk

 

 

 

Cantor Fitzgerald Europe

(Nominated Adviser and Joint Broker)

 

T: 020 7894 7000

David Foreman, Catherine Leftley, Corporate Finance

 

 

David Banks, Sales

 

 

 

 

 

Peterhouse Corporate Finance Limited

(Joint Broker)

 

T: 020 7469 0935

Lucy Williams

 

 

 

 

 

Kreab

 

T: 020 7074 1800

Robert Speed, Matthew Jervois

 

 

 

 

Notes to Editor:

 

About Frontier IP Group plc

www.frontierip.co.uk 

Frontier IP specialises in assisting institutions and companies in the commercialisation and exploitation of their intellectual property. It establishes formal and informal relationships with sources of exploitable IP, principally universities. Its core business is building and growing a portfolio of equity stakes in spin-out companies by taking an active involvement in the commercialisation and funding of these businesses.

 

About Universidade NOVA de Lisboa, Faculty of Science and Technology

http://www.fct.unl.pt

FCT NOVA is one of the most prestigious Portuguese engineering and science public schools and it is engaged in extensive research activity developed in 16 research centres involving 1600 PhD and Master's students and a total of 550 academic staff (90% holding a Ph.D). FCT NOVA partners with foreign universities such as the Massachusetts Institute of Technology (MIT), the University of Carnegie Mellon and the University of Texas at Austin to offer some of its advanced study programs. The entrepreneurial drive of the students and graduates of FCT NOVA has led to many successful spin-offs that transfer knowledge to the market and help create value and social impact.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRLLFSIARISLIR
Date   Source Headline
5th Dec 20227:00 amRNSThe Vaccine Group completes Lassa fever project
2nd Dec 20227:00 amRNSThe Vaccine Group completes vaccine project
30th Nov 20225:00 pmRNSTotal Voting Rights
25th Nov 20222:23 pmRNSDirector/PDMR Shareholding
23rd Nov 20225:17 pmRNSDirector share transfers
18th Nov 20223:53 pmRNSExercise of Options & PDMR Shareholdings
11th Nov 20223:07 pmRNSDirector/PDMR Dealing
11th Nov 20227:00 amRNSPosting of Annual Report and Notice of AGM
8th Nov 20227:00 amRNSPulsiv announces £1.5m fundraise
1st Nov 20221:46 pmEQSFrontier IP Group 'rigged for a storm' but confident of more progress
27th Oct 20227:00 amRNSFinal Results
19th Oct 20224:22 pmRNSHolding(s) in Company
19th Oct 20223:29 pmRNSHolding(s) in Company
14th Oct 20227:00 amRNSElute Intelligence appoints Steve Cable as CEO
27th Sep 20227:00 amRNSPulsiv unveils power electronics technology
18th Aug 20223:20 pmRNSSale of shares in Exscientia
5th Aug 20227:00 amRNSCamGraPhIC announces £1.26 million fundraising
26th Jul 20224:26 pmRNSHolding(s) in Company
26th Jul 20224:07 pmRNSHolding(s) in Company
24th May 20227:00 amRNSCambridge Raman Imaging raises £1.1 million
19th May 20227:00 amRNSPublication of newsletter
12th Apr 20225:18 pmRNSHolding(s) in Company
17th Mar 20227:00 amRNSUnaudited Half Year Results
14th Feb 20227:00 amRNSSale of shares in Exscientia
11th Feb 20225:04 pmRNSHolding(s) in Company
11th Feb 20222:05 pmRNSHolding(s) in Company
10th Feb 20227:00 amRNSCambridge Raman Imaging wins European Union grant
25th Jan 20227:00 amRNSSale of shares in Exscientia
17th Jan 20225:56 pmRNSHolding(s) in Company
12th Jan 20227:00 amRNSTrading update
11th Jan 20227:00 amRNSCelerum launch first commercial product
9th Dec 20212:33 pmRNSResult of AGM
29th Nov 20217:00 amRNSTVG - milestone in development of COVID-19 vaccine
9th Nov 20217:00 amRNSPosting of Annual Accounts and Notice of AGM
28th Oct 20217:00 amRNSDirectorate Change
28th Oct 20217:00 amRNSFinal Results
15th Oct 20217:00 amRNSPublication of newsletter
1st Oct 20217:59 amRNSPricing of IPO of Exscientia in the United States
30th Sep 20217:00 amRNSCamGraPhIC raises £1.6 million
27th Sep 20213:56 pmRNSUpdate on proposed IPO of Exscientia
24th Sep 20217:00 amRNSHolding(s) in Company
13th Sep 20217:00 amRNSExscientia - Statement filed for proposed IPO
8th Sep 20211:24 pmRNSExscientia enters $70M collaboration
8th Jul 20217:00 amRNSCamGraPhIC loan facility of up to £1.5 million
15th Jun 20217:00 amRNSPulsiv appoints Adam Westcott as CFO
14th Jun 20217:00 amRNSNandi Proteins appoints David Flower as CEO
11th Jun 20217:00 amRNSPublication of newsletter
24th May 20217:00 amRNSPulsiv complete £1.5m fundraising and appoints CEO
19th May 202111:53 amRNSExscientia collaboration with Bristol Myers Squibb
6th May 20217:00 amRNSThe Vaccine Group appoints Jeremy Salt as CEO

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.